Association of Androgen Deprivation Therapy With Dementia in Men With Prostate Cancer Who Receive Definitive Radiation Therapy
There is conflicting evidence on the association of androgen deprivation therapy (ADT) and dementia. Figure) . We excluded patients with a prior diagnosis of mild cognitive impairment, stroke, and dementia or a diagnosis of dementia within 1 year of PC diagnosis. Patients who underwent other treatment modalities, including radical prostatectomy, or who did not receive definitive treatment were excluded. Patients who initiated ADT more than 1 year after their PC diagnosis were excluded to avoid inclusion of patients with metastatic disease. Finally, patients who received chemotherapy as a component of their treatment were excluded because chemotherapy may be related to the development of dementia. This study was reviewed, approved, and granted a waiver of consent and authorization by the Veterans Affairs San Diego Health Care System. All data were deidentified.
The use of ADT in veterans with PC was assessed in a FineGray competing risks regression model through subdistribution hazard ratios (SHRs), and we considered death from any cause as a competing event to development of dementia. We assumed a 2-sided α = .05.
The primary outcome was new development of any form of dementia. Secondary outcomes included vascular dementia and Alzheimer disease. These outcomes were modeled as a function of ADT use, age, Charlson Comorbidity Index score, statin use, antiplatelet use, antihypertensive use, alcohol use, substance use, race, smoking status, region, income, educational level, and year of diagnosis. Sensitivity analysis with a time-varying definition of ADT was also conducted.
Results | The cohort included 45 218 men followed up for a median of 6.8 years (interquartile range, 4.1-9.9 years). During the study follow-up, 1497 patients were diagnosed with any dementia. Of these, 335 had vascular dementia, 404 had Alzheimer disease, and 758 had other or unclassified dementia. There was no statistically significant association between ADT use and any dementia (SHR, 1.04; 95% CI, 0.94-1.16; P = .43), vascular dementia (SHR, 1.20; 95% CI, 0.97-1.50; P = .10), or Alzheimer disease (SHR, 1.11; 95% CI, 0.91-1.36; P = .29) (Table) . Furthermore, no association was found between ADT length of 1 year or less with any dementia (SHR, 1.01; 95% CI, 0.89-1.15; P = .89) and ADT length greater than 1 year with any dementia (SHR, 1.08; 95% CI, 0.95-1.24; P = .21) (Table) . A sensitivity analysis using time-varying ADT exposure revealed no significant association between ADT and any dementia (SHR, 1.04; 95% CI, 0.94-1.16; P = .43), vascular dementia (SHR, 1.21; 95% CI, 0.97-1.50; P = .09), and Alzheimer disease (SHR, 1.11; 95% CI, 0.91-1.35; P = .29).
Discussion | Our cohort included more than 45 000 men who were treated in a relatively homogeneous fashion with definitive radiotherapy with or without ADT. The study has some Letters limitations. First, because our cohort focused on radiotherapytreated patients, the results of this study may not be generalizable to other patients with PC treated with other modalities. Second, our cohort included only veterans. Therefore, some differences in sociodemographic factors may exist that limit the generalizability of these results to the larger population of men with PC. We did not observe a statistically significant increase in risk of any dementia, vascular dementia, or Alzheimer disease. Furthermore, the effect sizes (SHRs, 1.00-1.21) were substantially lower than those seen in studies from Nead and colleagues 1,2 (HRs, 1.66-2.32), suggesting that our results were not attributable to inadequate power to detect these differences. These results may mitigate concerns regarding the long-term risks of ADT on cognitive health in the treatment of PC.
To the Editor Dhakal et al 1 used conventional meta-analysis techniques to address an important question regarding the efficacy of high-dose therapy followed by autologous stem cell transplant (HDT/ASCT) vs standard care in patients with multiple myeloma. The primary outcome was progression-free survival (PFS), with overall survival (OS) as a secondary end point. 
